User:Mr. Ibrahem/Olutasidenib

Olutasidenib, sold under the brand name Rezlidhia, is an medication used to treat acute myeloid leukemia. Specifically it is used in those with certain IDH1 mutations who have failed other treatments. It is taken by mouth.

Common side effects include nausea, tiredness, joint pain, constipation, shortness of breath, fever, rash, inflammation of the mouth, and diarrhea. Common lab abnormalities include high potassium, low sodium, liver problems, and kidney problems. Other side effects may include differentiation syndrome. It is an isocitrate dehydrogenase-1 (IDH1) inhibitor.

Olutasidenib was approved for medical use in the United States in 2022. In the United States it costs about 32,200 USD per month as of 2022.